Plano, TX, United States of America

Padmashree C G Rida

USPTO Granted Patents = 3 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017-2019

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Padmashree C G Rida

Introduction

Padmashree C G Rida is an accomplished inventor based in Plano, TX (US). He has made significant contributions to the field of medical diagnostics, particularly in the assessment of neoplastic tissues. With a total of 3 patents to his name, Rida's work is paving the way for advancements in cancer prognosis and treatment.

Latest Patents

Rida's latest patents include a groundbreaking method for determining the risk profile of neoplastic tissue. This method involves processing tumor tissue samples to visualize and analyze centrosomes, which are critical in understanding cancer severity. The steps include determining the numbers and volumes of individual centrosomes and calculating centrosome amplification scores (CASs) to provide a prognosis for patients. Another notable patent focuses on compositions and methods for assessing the prognosis of neoplasms by evaluating the mitotic cells to proliferating cells ratio (M:P ratio) in tissue samples.

Career Highlights

Rida is currently associated with Novazoi Theranostics, where he continues to innovate in the field of cancer diagnostics. His work is instrumental in developing protocols that enhance the accuracy of cancer prognosis, ultimately aiming to improve patient outcomes.

Collaborations

Rida collaborates with Ritu Aneja, a fellow researcher, to further advance their shared goals in cancer research and diagnostics.

Conclusion

Padmashree C G Rida's contributions to medical innovation are significant, particularly in the realm of cancer diagnostics. His patents reflect a commitment to improving patient care through advanced methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…